Stoke Therapeutics (NASDAQ:STOK) Releases Quarterly Earnings Results

by · The Cerbat Gem

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05, Zacks reports. The business had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%.

Stoke Therapeutics Price Performance

NASDAQ:STOK traded up $0.02 during mid-day trading on Thursday, hitting $13.27. The company’s stock had a trading volume of 280,079 shares, compared to its average volume of 760,807. The business’s fifty day moving average is $13.24 and its two-hundred day moving average is $13.70. The stock has a market cap of $698.64 million, a price-to-earnings ratio of -6.09 and a beta of 0.95. Stoke Therapeutics has a 1 year low of $3.77 and a 1 year high of $17.58.

Wall Street Analyst Weigh In

STOK has been the subject of several recent analyst reports. Wedbush restated an “outperform” rating and issued a $17.00 target price on shares of Stoke Therapeutics in a research note on Thursday, July 11th. Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. Finally, Leerink Partners assumed coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price for the company. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics has a consensus rating of “Buy” and a consensus price target of $20.83.

Get Our Latest Stock Report on STOK

Insider Activity

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of the firm’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the sale, the insider now directly owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 11.30% of the company’s stock.

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Featured Articles